Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma

被引:2
作者
DavidgePitts, M [1 ]
Dansey, R [1 ]
Bezwoda, WR [1 ]
机构
[1] UNIV WITWATERSRAND, SCH MED, DIV CLIN HEMATOL & MED ONCOL, DEPT MED, ZA-2193 PARKTOWN, JOHANNESBURG, SOUTH AFRICA
关键词
follicular non-Hodgkin's lymphoma; salvage chemotherapy; prognostic factors;
D O I
10.3109/10428199709039022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In an attempt to further define prognostic factors in patients with follicular non-Hodgkin's lymphoma, two subgroups of patients receiving 2nd line therapy; (a) those who had failed to achieve CR with initial therapy and (b) those who had relapsed after achieving initial CR, were examined. Patients who failed to achieve initial remission were not totally refractory to retreatment. Seven of 34 (21%) who had failed to respond to initial treatment achieved CR following treatment with various 'salvage chemotherapy' approaches. There were, however, no significant pretreatment prognostic factors that were predictive for response. Among patients who relapsed after initial CR, 22 of 54 (41%) achieved a second CR following retreatment with conventional chemotherapy approaches. The only factors which were significant in predicting for second CR were sex (female) and age (< 60 years), In both subgroups, patients who achieved CR following 'salvage' therapy survived significantly longer than those who responded less favourably. These findings emphasise the fact that response to treatment is the major predictor of survival among patients with indolent non-Hodgkin's lymphomas.
引用
收藏
页码:341 / 347
页数:7
相关论文
共 41 条
[1]  
AINENBERG AC, 1993, ANNU REV MED, V44, P75
[2]  
ANDERSON T, 1982, CANCER-AM CANCER SOC, V50, P2708, DOI 10.1002/1097-0142(19821215)50:12<2708::AID-CNCR2820501203>3.0.CO
[3]  
2-G
[4]  
ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023
[5]   MITOXANTRONE - AN ACTIVE AGENT IN REFRACTORY NON-HODGKINS LYMPHOMAS [J].
BAJETTA, E ;
BUZZONI, R ;
VALAGUSSA, P ;
BONADONNA, G .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (02) :100-103
[6]   IDENTIFICATION OF THE GENE ASSOCIATED WITH THE RECURRING CHROMOSOMAL TRANSLOCATIONS T(3,14)(Q27,Q32) AND T(3,22)(Q27,Q11) IN B-CELL LYMPHOMAS [J].
BARON, BW ;
NUCIFORA, G ;
MCCABE, N ;
ESPINOSA, R ;
LEBEAU, MM ;
MCKEITHAN, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) :5262-5266
[7]   FOLLICULAR LYMPHOAMS - ASSESSMENT OF PROGNOSTIC FACTORS IN 127 PATIENTS FOLLOWED FOR 10 YEARS [J].
BASTION, Y ;
BERGER, F ;
BRYON, PA ;
FELMAN, P ;
FFRENCH, M ;
COIFFIER, B .
ANNALS OF ONCOLOGY, 1991, 2 :123-129
[8]  
BITRAN JD, 1978, CANCER, V42, P88, DOI 10.1002/1097-0142(197807)42:1<88::AID-CNCR2820420115>3.0.CO
[9]  
2-U
[10]   OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY NONHODGKINS LYMPHOMA REFERRED FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRANDWEIN, JM ;
SMITH, AM ;
LANGLEY, GR ;
BURNELL, M ;
SUTCLIFFE, SB ;
KEATING, A .
LEUKEMIA & LYMPHOMA, 1991, 4 (04) :231-238